Held 1st - 2nd April 2022

Accessing ProsTIC Preceptorship 2022 – On Demand Presentations
Preceptorship themes
PSMA PET/CT
What is the role of PSMA PET/CT in early stage prostate cancer?
Evidence
Evidence-based PSMA
Biomarkers
Is PSMA PET/CT a new biomarker for optimising patient management?
Advocates
Consumer advocates
Theranostic Suite
The Theranostic Suite: How we run it from 5 perspectives
PSMA Theranostics
The art of PSMA theranostics
Welcome
It is with delight and pleasure that I invite, and warmly welcome you to the inaugural ProsTIC Preceptorship 2022, in-person or online.
In line with one of our program’s key pillars of Education and Leadership, we are proud to present “How we do PSMA Theranostics”.
Together with multidisciplinary colleagues and world leading experts we will provide you with the latest in research, case studies, practical applications and the future of PSMA Imaging and Theranostics.
We performed our first PSMA PET/CT in 2014, and our first Lutetium PSMA therapy in 2015. We will share with you how we, at the Peter MacCallum Cancer Centre, “do” our successful program, so you can too!
Kind regards,
Professor Michael Hofman
Chair, ProsTIC Preceptorship 2022
Director, Prostate Cancer Theranostics and Imaging Centre of Excellence
Preceptorship Updates
8:30am – 10:30am
Our stellar program opens with a deep dive into the role of PSMA PET/CT in early-stage prostate cancer. Prof Wolfgang Fendler and Prof Thomas Hope support our local experts including Prof. Louise Emmett.
1:30pm – 3:30pm
From TheraP to treatment combination trials, join experts Prof Silke Gillessen and A/Prof Shahneen Sandhu to provide insights on how we utilise PSMA radioligand therapy.
4:00pm – 5:30pm
For behind the scenes action on how the Peter Mac team run a theranostics suite, we explore all of the multidisciplinary perspectives.
8:00am – 9:00am
Go beyond the images and discover what’s around the corner for PSMA theranostics with Dr Heidi Fettke and Dr Andrei Gafita.
11.00am – 12.30pm
In a world first, join Professor Thomas Hope, Professor Michael Hofman and Professor Declan Murphy, as they HARDtalk the hot topics and hard hitting questions of “The current state of PSMA” and “What’s coming next”.

Accelerate clinical trial research
Accelerate clinical trial research
Expand the portfolio of clinical trials investigating the use of PSMA PET imaging and therapy targeting areas of high-impact need that are not currently being addressed.

Education & Leadership
Education & Leadership
Establish a global hub of excellence to educate doctors, scientists, patients and the community about the application and benefits of this new technology.

Discovery research
Discovery research
Further investigate next generation targets, develop biomarkers to predict and monitor response to PSMA therapy, optimise new combinations with PSMA therapy in pre-clinical models, explore the use of radio-guided surgery and artificial intelligence image interpretation.